Investors in Inovio Pharmaceuticals (INO +0.6%) do not appear overly concerned (at least not yet) with a bearish report from short-seller Citron Research who says the company is COVID-19’s version of former high-flier Theranos.
Both companies have touted a “secret sauce” as
their technology edge. In Inovio’s case, it is a computer algorithm that
generated a vaccine design in three hours.
Citron sees 93% downside risk ($1 price target) from current levels.
https://seekingalpha.com/news/3564655-inovio-shrugs-off-bearish-citron-report-up-1
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.